Effects of Statin Therapy on the Production of Monocyte Pro-Inflammatory Cytokines, Cardiac Function, and Long-Term Prognosis in Chronic Heart Failure Patients With Dyslipidemia

• Nakagomi Akihiro

  Department of Internal Medicine and Cardiology, Tama-Nagayama Hospital, Nippon Medical School

• Seino Yoshihiko

  Department of Cardiology, Nippon Medical School Chiba-Hokusoh Hospital

• Kohashi Keiichi

  Department of Internal Medicine and Cardiology, Tama-Nagayama Hospital, Nippon Medical School

• Kosugi Munenori

  Department of Internal Medicine and Cardiology, Tama-Nagayama Hospital, Nippon Medical School

• Endoh Yasumi

  Department of Internal Medicine and Cardiology, Tama-Nagayama Hospital, Nippon Medical School

• Kusama Yoshiki

  Department of Internal Medicine and Cardiology, Tama-Nagayama Hospital, Nippon Medical School

• Atarashi Hirotsugu

  Department of Internal Medicine and Cardiology, Tama-Nagayama Hospital, Nippon Medical School

• Mizuno Kyoichi

  Department of Internal Medicine (Division of Cardiology, Hepatology, Geriatrics, and Integrated Medicine), Nippon Medical School

抄録

Background: The effects of statin therapy on the production of monocyte pro-inflammatory cytokines, cardiac function and the long-term prognosis in chronic heart failure (CHF) patients with dyslipidemia remain unclear. Methods and Results: A total of 146 CHF patients with a mean left ventricular ejection fraction (LVEF) of 26.9±6.6% were divided into 2 groups based on whether or not statins were included in their treatment: a statin group (n=63) and a no statin group (n=83). Only patients with dyslipidemia were treated with statins. Peripheral blood mononuclear cells (PBMCs) were isolated, and the production of monocyte tumor necrosis factor (TNF)-α and interleukin (IL)-6 were measured at baseline and after 6 months of treatment, and the data expressed as mean±SD (pg·ml^–1·10^–6 PBMCs). The LVEF in the statin group improved, and the monocyte TNF-α and IL-6 production decreased (respectively, P<0.001), but the LVEF and cytokine production remained unchanged in the no statin group. Multivariate Cox hazard analysis showed that statin therapy (hazard ratio, 0.14; 95% confidence interval: 0.02–0.97, P=0.046) was an independent predictor of cardiac events. Conclusions: Statin therapy attenuates the production of monocyte pro-inflammatory cytokines, and ameliorates the cardiac function and may improve long-term prognosis in CHF patients with dyslipidemia.  (Circ J 2012; 76: 2130–2138)<br>

収録刊行物

• Circulation Journal

  Circulation Journal 76 (9), 2130-2138, 2012

  一般社団法人 日本循環器学会

キーワード

• Cytokine
• Dyslipidemia
• Heart failure
• Statin

詳細情報

• CRID: 1390282680080191744
• NII論文ID: 10030696511
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.cj-11-1123
• COI: 1:CAS:528:DC%2BC38XhtlOmsrrF
• ISSN: 13474820
• ISSN: 13469843
• PubMed: 22785006
• Web Site: https://www.jstage.jst.go.jp/article/circj/76/9/76_CJ-11-1123/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2013306607
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可